Endo Health Solutions announced that its wholly owned subsidiary, HealthTronics, has entered into a definitive agreement to sell its anatomical pathology business, HealthTronics Laboratory Solutions, to Metamark Genetics for an undisclosed amount. As previously announced Endo Health Solutions is pursuing strategic alternatives for HealthTronics and believes the sale of HLS creates progress in this process. Metamark is at the leading edge of research in cancer prognosis, which is a critical tool in determining appropriate cancer therapy. In the age of personalized medicine, particularly in oncology, Metamark's proprietary multiplex proteomic platform has the potential to reshape the landscape in cancer diagnosis and therapy.
- Health Care Industry